WO2011040973A3 - Immunoconjugués de tnf avec des anticorps de protéine d'activation des fibroblastes et procédés et utilisations de ceux-ci - Google Patents

Immunoconjugués de tnf avec des anticorps de protéine d'activation des fibroblastes et procédés et utilisations de ceux-ci Download PDF

Info

Publication number
WO2011040973A3
WO2011040973A3 PCT/US2010/002661 US2010002661W WO2011040973A3 WO 2011040973 A3 WO2011040973 A3 WO 2011040973A3 US 2010002661 W US2010002661 W US 2010002661W WO 2011040973 A3 WO2011040973 A3 WO 2011040973A3
Authority
WO
WIPO (PCT)
Prior art keywords
fap
immunoconjugates
tnf
antibodies
fragments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2010/002661
Other languages
English (en)
Other versions
WO2011040973A2 (fr
Inventor
Stefan Bauer
Thomas Wuest
Christoph Renner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ludwig Institute for Cancer Research Ltd
Ludwig Cancer Research
Original Assignee
Ludwig Institute for Cancer Research Ltd
Ludwig Cancer Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Institute for Cancer Research Ltd, Ludwig Cancer Research filed Critical Ludwig Institute for Cancer Research Ltd
Publication of WO2011040973A2 publication Critical patent/WO2011040973A2/fr
Publication of WO2011040973A3 publication Critical patent/WO2011040973A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nanotechnology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention porte sur des immunoconjugués de protéine, en particulier des conjugués de TNF avec des anticorps et des fragments de ceux-ci qui se lient à la protéine d'activation des fibroblastes (FAP). L'invention propose des conjugués TNF-anticorps anti-FAP dans lesquels l'anticorps anti-FAP reconnaît à la fois le FAP humain et le FAP de souris. Ces immunoconjugués sont utiles dans le diagnostic et le traitement d'états associés à un stroma activé comprenant une cicatrisation, des cancers épithéliaux, l'arthrose, la polyarthrite rhumatoïde, la cirrhose et la fibrose pulmonaire et de façon plus large dans des états et troubles sensibles à TNF, comprenant le cancer et les maladies hyperprolifératives. De plus, les immunoconjugués anti-FAP peuvent être utilisés pour le diagnostic et le traitement de tumeurs positives à FAP telles que le cancer pancréatique, les mélanomes et les sarcomes. Les immunoconjugués, anticorps, les régions variables ou séquences de domaine CDR de ceux-ci et fragments de ceux-ci de la présente invention peuvent également être utilisés en thérapie en combinaison avec des agents chimiothérapeutiques, des modulateurs de l'immunité ou des agents anticancéreux et/ou avec d'autres anticorps ou fragments de ceux-ci.
PCT/US2010/002661 2009-10-02 2010-10-01 Immunoconjugués de tnf avec des anticorps de protéine d'activation des fibroblastes et procédés et utilisations de ceux-ci Ceased WO2011040973A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27806509P 2009-10-02 2009-10-02
US61/278,065 2009-10-02

Publications (2)

Publication Number Publication Date
WO2011040973A2 WO2011040973A2 (fr) 2011-04-07
WO2011040973A3 true WO2011040973A3 (fr) 2011-11-24

Family

ID=43708803

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/002661 Ceased WO2011040973A2 (fr) 2009-10-02 2010-10-01 Immunoconjugués de tnf avec des anticorps de protéine d'activation des fibroblastes et procédés et utilisations de ceux-ci

Country Status (1)

Country Link
WO (1) WO2011040973A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116474108A (zh) 2016-12-14 2023-07-25 普渡研究基金会 成纤维细胞活化蛋白(fap)-靶向成像和治疗
EP3634485A4 (fr) * 2017-06-07 2021-07-21 Silverback Therapeutics, Inc. Conjugués d'anticorps constitués de composés immunomodulateurs et leurs utilisations
CN112402597B (zh) * 2020-11-26 2022-04-01 四川大学 一种fap修饰的类外泌体纳米囊泡肿瘤疫苗
CN112522388A (zh) * 2020-12-18 2021-03-19 上海市东方医院（同济大学附属东方医院） 成纤维细胞激活蛋白作为药物靶点在治疗骨关节炎中的用途
CN120383679A (zh) * 2021-06-23 2025-07-29 南京江原安迪科正电子研究发展有限公司 抗FAP单域抗体、Fc融合蛋白、免疫缀合物及其应用
WO2024199269A1 (fr) * 2023-03-27 2024-10-03 Suzhou Fuse Biosciences Limited Immunoconjugués contenant du tnf-alpha et procédés associés et compositions associées
CN119053628A (zh) * 2023-12-18 2024-11-29 苏州智核生物医药科技有限公司 Fap结合多肽及其用途
WO2025140212A1 (fr) * 2023-12-26 2025-07-03 Laekna Therapeutics Shanghai Co., Ltd. Agents de liaison multispécifiques comprenant des anticorps anti-protéine d'activation des fibroblastes (fap) et un ou plusieurs pièges à ligands monovalents et leurs utilisations

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1806365A1 (fr) * 2006-01-05 2007-07-11 Boehringer Ingelheim International GmbH Anticorps spécifiques pour la protéine alpha d'activation de fibroblastes et leurs immunoconjugués
WO2011020783A2 (fr) * 2009-08-17 2011-02-24 Roche Glycart Ag Immunoconjugués ciblés
WO2011040972A1 (fr) * 2009-10-02 2011-04-07 Ludwig Institute For Cancer Research Ltd. Anticorps dirigés contre la protéine d'activation du fibroblaste, et utilisations et procédés correspondants

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3654090A (en) 1968-09-24 1972-04-04 Organon Method for the determination of antigens and antibodies
USRE31006E (en) 1968-09-24 1982-08-03 Akzona Incorporated Process for the demonstration and determination of reaction components having specific binding affinity for each other
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US4016043A (en) 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
US5587299A (en) 1994-04-20 1996-12-24 Memorial Sloan-Kettering Cancer Center Isolated nucleic acid molecule coding for fibroblast activation protein alpha and uses thereof
US6306393B1 (en) 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US7381801B2 (en) 2002-02-13 2008-06-03 Ludwig Institute For Cancer Research Chimerized GM-CSF antibodies

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1806365A1 (fr) * 2006-01-05 2007-07-11 Boehringer Ingelheim International GmbH Anticorps spécifiques pour la protéine alpha d'activation de fibroblastes et leurs immunoconjugués
WO2011020783A2 (fr) * 2009-08-17 2011-02-24 Roche Glycart Ag Immunoconjugués ciblés
WO2011040972A1 (fr) * 2009-10-02 2011-04-07 Ludwig Institute For Cancer Research Ltd. Anticorps dirigés contre la protéine d'activation du fibroblaste, et utilisations et procédés correspondants

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BAUER: "Structure-activity profiles of Ab-derived TNF fusion proteins", THE JOURNAL OF IMMUNOLOGY, vol. 177, no. 4, 1 January 2006 (2006-01-01), pages 2423, XP055005063, ISSN: 0022-1767 *
BAUER: "Targeted bioactivity of membrane-anchored TNF by an antibody-derived TNF fusion protein", THE JOURNAL OF IMMUNOLOGY, vol. 172, no. 6, 1 January 2004 (2004-01-01), pages 3930, XP055005065, ISSN: 0022-1767 *
MESSERSCHMIDT S K E ET AL: "Targeted lipid-coated nanoparticles: Delivery of tumor necrosis factor-functionalized particles to tumor cells", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 137, no. 1, 1 July 2009 (2009-07-01), pages 69 - 77, XP026161200, ISSN: 0168-3659, [retrieved on 20090321], DOI: 10.1016/J.JCONREL.2009.03.010 *
OSTERMANN E ET AL: "Effective Immunoconjugate Therapy in Cancer Models Targeting a Serine Protease of Tumor Fibroblasts", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 14, no. 14, 15 July 2008 (2008-07-15), pages 4584 - 4592, XP002612452, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-07-5211 *
RETTIG ET AL: "fibroblast activation protein: purification, epitope mapping and induction by growth factors", INTERNATIONAL JOURNAL OF CANCER, JOHN WILEY & SONS, INC, UNITED STATES, SWITZERLAND, GERMANY, vol. 58, 1 August 1994 (1994-08-01), pages 385 - 392, XP002114043, ISSN: 0020-7136, DOI: 10.1002/IJC.2910580314 *
STEFAN BAUER ET AL: "Sequential cancer immunotherapy: targeted activity of dimeric TNF and IL-8", CANCER IMMUNITY, vol. 9, 9 March 2009 (2009-03-09), pages 2, XP055005057 *

Also Published As

Publication number Publication date
WO2011040973A2 (fr) 2011-04-07

Similar Documents

Publication Publication Date Title
WO2011040973A3 (fr) Immunoconjugués de tnf avec des anticorps de protéine d'activation des fibroblastes et procédés et utilisations de ceux-ci
SG178602A1 (en) Dual variable domain immunoglobulins and uses thereof
MX2012001262A (es) Inmunoglobulinas de dominio variable doble y usos de las misma.
MX2011011669A (es) Inmunoglobulinas de dominio variable dual y usos de las misma.
WO2009073533A3 (fr) Conjugués anticorps monoclonal-médicaments anti-b7h4 et procédés d'utilisation associés
WO2009055343A3 (fr) Anticorps anti-vegf entièrement humains et leurs procédés d'utilisation
WO2010066803A3 (fr) Anticorps humains du facteur tissulaire
NZ612394A (en) Tnf-α binding proteins
WO2010096434A3 (fr) Protéines de liaison spécifique et leurs utilisations
MY171007A (en) Bispecific binding molecules binding to vegf and ang2
WO2011025964A3 (fr) Protéines thérapeutiques se liant à dll4
WO2010127294A3 (fr) Immunoglobulines à deux domaines variables et leurs utilisations
TW201206473A (en) Dual variable domain immunoglobulins and uses thereof
PH12013500337A1 (en) Dual variable domain immunoglobulins and uses thereof
PH12013500867A1 (en) Dual variable domain immunoglobulins and uses thereof
WO2011050262A3 (fr) Immunoglobulines à domaine variable double et utilisations de celles-ci
WO2011059755A3 (fr) Immunoglobulines doubles de domaine variable et utilisations de celles-ci
WO2011047262A3 (fr) Immunoglobulines à deux domaines variables et utilisations afférentes
WO2011163478A3 (fr) Immunoglobulines à double domaine variable et utilisations associées
NZ599875A (en) Human il-23 antigen binding proteins
PH12014502527B1 (en) St2 antigen binding proteins
AU2010310545A8 (en) Anti-GCC antibody molecules and related compositions and methods
WO2011041319A8 (fr) Protéines de liaison spécifiques et leurs utilisations
NZ607588A (en) Antibodies against human TWEAK and uses thereof
WO2013043070A3 (fr) Agents du facteur de nécrose tumorale alpha et utilisations de ceux-ci

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10777122

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 11.06.2012)

122 Ep: pct application non-entry in european phase

Ref document number: 10777122

Country of ref document: EP

Kind code of ref document: A2